Page last updated: 2024-08-21

quinazolines and Ectopic Ossification

quinazolines has been researched along with Ectopic Ossification in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Bullock, AN; Eekhoff, EMW; Keen, R; Smilde, BJ; Stockklausner, C; van Schoor, NM; von Delft, A; Whittaker, A; Yu, PB	1
Bagarova, J; Bocobo, GA; Bullock, AN; Dey, D; Economides, AN; Huang, X; Kerr, G; Lee, A; Mohedas, AH; Place, ES; Sanderson, PE; Shen, Y; Smith, JC; Williams, E; Xia, DD; Yu, PB; Zheng, W	1
Hino, K; Horigome, K; Ikeya, M; Komura, S; Nagata, S; Nishio, M; Ohta, A; Okanishi, Y; Toguchida, J; Yamada, Y; Zhao, C	1
Iwase, T; Kishimoto, Y; Mori, H; Yano, T	1

Trials

1 trial(s) available for quinazolines and Ectopic Ossification

Article	Year
Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP). BMC musculoskeletal disorders, 2022, Jun-01, Volume: 23, Issue:1 Topics: Adolescent; Adult; Aged; Benzodioxoles; Double-Blind Method; Humans; Middle Aged; Multicenter Studies as Topic; Mutation; Myositis Ossificans; Ossification, Heterotopic; Quinazolines; Randomized Controlled Trials as Topic; Young Adult	2022

Article

Year

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).

BMC musculoskeletal disorders, 2022, Jun-01, Volume: 23, Issue:1

Topics: Adolescent; Adult; Aged; Benzodioxoles; Double-Blind Method; Humans; Middle Aged; Multicenter Studies as Topic; Mutation; Myositis Ossificans; Ossification, Heterotopic; Quinazolines; Randomized Controlled Trials as Topic; Young Adult

2022

Other Studies

3 other study(ies) available for quinazolines and Ectopic Ossification

Article	Year
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI insight, 2021, 04-22, Volume: 6, Issue:8 Topics: Activin Receptors, Type I; Animals; Benzodioxoles; Bone Morphogenetic Proteins; Drug Evaluation, Preclinical; Gene Knock-In Techniques; Mice; Mice, Transgenic; Muscles; Myositis Ossificans; Ossification, Heterotopic; Quinazolines; Zebrafish	2021
An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva. Stem cell reports, 2018, 11-13, Volume: 11, Issue:5 Topics: Activin Receptors, Type I; Animals; Benzodioxoles; High-Throughput Screening Assays; Humans; Induced Pluripotent Stem Cells; Mice, SCID; Mice, Transgenic; Myositis Ossificans; Ossification, Heterotopic; Oxazoles; Pyrimidines; Quinazolines; Reproducibility of Results; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Urea	2018
Reossification of osteolytic metastases at the acetabulum following gefitinib and multidisciplinary treatment for lung cancer: a case report with autopsy findings. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2015, Volume: 20, Issue:5 Topics: Acetabulum; Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Autopsy; Biopsy; Bone Neoplasms; Disease Progression; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Ossification, Heterotopic; Quinazolines; Tomography, X-Ray Computed	2015